Mini-HTA for Tendyne Mitral Valve System released in Norway

15

Apr 2020

Norway established in 2013 a framework for the introduction of innovations into the health care system through either a national or hospital-based health technology assessment. This framework is called the “New Method.”

In this framework, all innovations should undergo HTA before being funded. If the method concerns only one or two hospitals, the assessment shall be initiated by clinicians and ran at the hospital level. The final report is disseminated via a mini-HTA database. If the method is of national concern, it undergoes Single Technology Appraisal at the national level, followed by the funding decision by the group of payers (Decision Forum, Beslutningsforum).

At the end of February 2020, a completed mini-method assessment for the Tendyne Mitral Valve System was released. The Tendyne is a bioprosthesis designed for transapical implantation within the native mitral valve without the need for open-heart surgery and concomitant surgical removal of the failed native valve. The following conclusions were provided:

  • The good level of efficacy was shown by the studied method in comparison with the current treatment of mitral regurgitation that includes medical management, surgical repair or replacement of the mitral valve, transcatheter mitral valve repair (TMVr)
  • The method was determined as safe in comparison with the current treatment of mitral regurgitation
  • The method should be introduced as part of the clinical routine in the hospital
  • It is specifically outlined that the patients should be followed up like surgical replacement patients

See the full details in Norwegian here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

08

Jun 2023

In the period of April-May 2023, the Galician Agency for Health Technology Assessment (AVALIA-T) initiated the five health technology assessments referred to IVD, nephrology and urology, obstetrics and gynecology, pulmonary and airways as well as surgical procedures technology groups. The assessments on stereotactic virtual navigation system for percutaneous puncture as well as tumor ablation and invasive telemonitoring of pulmonary pressure in patients with heart failure were released.

Read more

07

Jun 2023

In May 2023, the National Institute for Health and Care Excellence (NICE) published one new Interventional Procedure Guidance (intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries), two new Diagnostic Guidance (MRI fusion biopsy systems for diagnosing prostate cancer, automated ankle-brachial pressure index measurement devices to detect peripheral arterial disease), and three new Health Technology Evaluations (Digitally enabled therapies for adults with anxiety disorders / with depression, and point-of-care tests for urinary tract infections). Also, four clinical guidelines were updated.

Read more

05

Jun 2023

In May 2023, NICE announced that the Medtech innovation briefing (MIB) program was discontinued. MIBs were a part of the advice program at NICE commissioned by NHS England in 2014 to support the 5-Year Forward View and accelerate innovations. NICE will now focus on introducing new approaches to evaluating the most promising health technologies.

Read more

31

May 2023

In May 2023, the government revised the national budget and proposed changes in the central health administration's roles, organization, and responsibilities to be implemented on January 1, 2024. The reorganization includes the merger of the Directorate of Health and the Directorate of e-Health.

Read more

26

May 2023

In late May 2023, the Norwegian Directorate of e-Health released an updated version of the Norwegian Laboratory code (NLK) system to be implemented no later than July 1, 2023. A total of 142 new codes were added, 33 codes were terminated, and 122 codes were amended.

Read more